Subtype
Sex Cord-Stromal Tumor
CI-CAN-00001503Explore in graph →
Non-malignant8 active trials11 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001503Explore in graph →
Clinical trials
25 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | recruiting | Phase 2 | 314 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT01247597 | DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study | recruiting | — | 1,500 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05348356 | Nirogacestat in Ovarian Granulosa Cell Tumors | completed | Phase 2 | 53 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 3 | Aug 25, 2026 | clinicaltrials |
Data updated 14 hours agoSource updated Sep 29, 2026source: clinicaltrials
| Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors |
| active not recruiting |
| Phase 2 |
| 17 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Jul 28, 2026 |
| clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT05872204 | Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer(ALEPRO) | recruiting | Phase 2 | 100 | Universitaire Ziekenhuizen KU LeuvenOTHER | 3 | May 5, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03418844 | Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy(VIVROVAIRE TR) | active not recruiting | N/A | 268 | Centre Francois BaclesseOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT03382158 | International PPB/DICER1 Registry | recruiting | — | 3,400 | Children's Hospitals and Clinics of MinnesotaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT01970696 | International Ovarian & Testicular Stromal Tumor Registry(OTST) | recruiting | — | 300 | Children's Hospitals and Clinics of MinnesotaOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03926936 | FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study(FUCHSia) | completed | Phase 2 | 17 | Frederic AmantOTHER | 2 | May 28, 2024 | clinicaltrials |
| NCT06328491 | Erdafitinib in Metastatic Steroid-cell Ovarian Cancer | completed | N/A | 1 | University Health Network, TorontoOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06254781 | Luspatercept in Metastatic AGCT of the Ovary | completed | N/A | 1 | University Health Network, TorontoOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT02429700 | TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors(SCST-01) | recruiting | Phase 3 | 132 | Beihua KongOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT00565903 | Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome(PPB) | completed | — | 1,247 | Ashley HillOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT01042522 | Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors | unknown | Phase 2 | 63 | GOG FoundationNETWORK | 1 | Jan 25, 2022 | clinicaltrials |
| NCT01770301 | Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR)(ALIENOR) | completed | Phase 2 | 60 | ARCAGY/ GINECO GROUPOTHER | 1 | Jul 2, 2021 | clinicaltrials |
| NCT00006227 | Paclitaxel in Treating Patients With Ovarian Stromal Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 2 | Mar 5, 2020 | clinicaltrials |
| NCT00748657 | Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT02101684 | Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.(Greko II) | terminated | Phase 2 | 10 | Grupo Español de Tumores Huérfanos e InfrecuentesOTHER | 1 | Mar 5, 2018 | clinicaltrials |
| NCT01572467 | Studying Genes in Samples From Younger Patients With Ovarian or Testicular Sex Cord Stromal Tumors | completed | — | 50 | Children's Oncology GroupNETWORK | 0 | Jul 14, 2016 | clinicaltrials |
| NCT01764789 | Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer | completed | N/A | 39 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Oct 9, 2015 | clinicaltrials |
| NCT01652794 | Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer | completed | Phase 1 | 12 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 4, 2015 | clinicaltrials |
| NCT01584297 | Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary(GreKo) | terminated | Phase 2 | 6 | Grupo Español de Tumores Huérfanos e InfrecuentesOTHER | 1 | Jan 21, 2015 | clinicaltrials |